Intervention

Setmelanotide

ClinicalTrials.gov intervention label

Clinical trials19
Recruiting2
Common conditions25
Lead sponsors shown3

Clinical trials

19 shown
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546 · 2025-09-23
RECRUITING
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesityNCT07674290 · 2023-01-01
RECRUITING
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)NCT07496463 · 2026-07-21
ENROLLING_BY_INVITATION
A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597 · 2025-03-04
ACTIVE_NOT_RECRUITING
Open-Label Extension Study of SetmelanotideNCT06596135 · 2024-10-21
COMPLETED
A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756 · 2023-04-26
ACTIVE_NOT_RECRUITING
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNCT04966741 · 2022-03-08
COMPLETED
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayNCT05093634 · 2021-12-10
COMPLETED
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayNCT04963231 · 2021-11-30
COMPLETED
Open-Label Study of Setmelanotide in Hypothalamic ObesityNCT04725240 · 2021-06-07
COMPLETED
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityNCT03746522 · 2018-11-23
COMPLETED
Long Term Extension Trial of SetmelanotideNCT03651765 · 2018-07-15
COMPLETED
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityNCT03287960 · 2018-01-30
COMPLETED
Setmelanotide in a Single Patient With Partial LipodystrophyNCT03262610 · 2017-08-15
COMPLETED
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192 · 2017-02-14
COMPLETED
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543 · 2017-02-10
COMPLETED
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673 · 2015-03-19
COMPLETED
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsNCT02041195 · 2014-01-01
COMPLETED
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsNCT01749137 · 2013-01-14
COMPLETED

Common conditions

Obesity5Genetic Obesity3Hypothalamic Obesity3Bardet Biedl Syndrome (BBS)2Obesity Associated With Defects in Leptin-melanocortin Pathway2Prader-Willi Syndrome2Alstrom Syndrome1Alström Syndrome (AS)1Bardet Biedl Syndrome1Bardet-Biedl Syndrome1Bardet-Biedl Syndrome (BBS)1Childhood-onset Combined Pituitary Hormone Deficiency1Hyperphagia1Hypertriglyceridemia1LEPR Deficiency Obesity1Leptin Receptor Deficiency Obesity1Multiple Pituitary Hormone Deficiency Genetic Form1Obesity Due to Melanocortin 4 Receptor Deficiency1Optic Nerve Hypoplasia1Overweight1Overweight and Obesity1PCSK1 Deficiency Obesity1Pituitary Stalk Interruption Syndrome1POMC Deficiency Obesity1Pro-opiomelanocortin (POMC) Deficiency Obesity1

Trial status mix

COMPLETED14
ACTIVE_NOT_RECRUITING2
RECRUITING2
ENROLLING_BY_INVITATION1

Phase mix

PHASE210
PHASE39
PHASE11
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.